Industrial biotech pioneer Amyris (NASDAQ: AMRS)appears to have successfully walked a risky tightrope in the last year to deliver some impressive gains to shareholders. The stock is up 80% year-to-date and up 104% since completing a reverse stock split in June 2017 that reduced the number of shares outstanding by a factor of 15.
This Biotech Stock is Up 80% in 2018, but Is Its Business Model Sound?
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться